UY39658A - Formulación y métodos de gliburida de baja absorción - Google Patents

Formulación y métodos de gliburida de baja absorción

Info

Publication number
UY39658A
UY39658A UY0001039658A UY39658A UY39658A UY 39658 A UY39658 A UY 39658A UY 0001039658 A UY0001039658 A UY 0001039658A UY 39658 A UY39658 A UY 39658A UY 39658 A UY39658 A UY 39658A
Authority
UY
Uruguay
Prior art keywords
methods
glyburide
low absorption
delivering
solution
Prior art date
Application number
UY0001039658A
Other languages
English (en)
Inventor
Kenny K Tran
Deirdre Lowe
Rupa Rishikesh Sawant
Haihong Chen
Yiqing Lin
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of UY39658A publication Critical patent/UY39658A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/58—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Métodos y formulaciones para minimizar o evitar la sorción de gliburida en las superficies de los tubos de suministro, filtros, bolsas y otros recipientes y materiales, almacenando y suministrando así un producto más estable, suministrando una dosis predecible y precisa de la gliburida, al tiempo que minimiza las impurezas, evita el desperdicio de medicamentos, reduce los costos y reduce significativamente la cantidad de solución de dosificación (generalmente solución salina o solución de Ringer) que se debe infundir al paciente.
UY0001039658A 2021-03-04 2022-03-04 Formulación y métodos de gliburida de baja absorción UY39658A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163156533P 2021-03-04 2021-03-04

Publications (1)

Publication Number Publication Date
UY39658A true UY39658A (es) 2022-09-30

Family

ID=80930067

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039658A UY39658A (es) 2021-03-04 2022-03-04 Formulación y métodos de gliburida de baja absorción

Country Status (11)

Country Link
US (1) US20220280537A1 (es)
EP (1) EP4301337A2 (es)
JP (1) JP2024512310A (es)
KR (1) KR20230165778A (es)
CN (1) CN117320727A (es)
AR (1) AR125033A1 (es)
CA (1) CA3210407A1 (es)
MX (1) MX2023010313A (es)
TW (1) TW202302117A (es)
UY (1) UY39658A (es)
WO (1) WO2022187567A2 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
CN101299983B (zh) 2005-10-30 2012-01-11 麦迪麦珀医疗工程有限公司 无针式附加剂控制阀
JP3205560U (ja) 2013-08-07 2016-08-04 メディモップ・メディカル・プロジェクツ・リミテッド 点滴液容器とともに使用するための液体移送デバイス
CN108210501B (zh) * 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法

Also Published As

Publication number Publication date
KR20230165778A (ko) 2023-12-05
AR125033A1 (es) 2023-05-31
TW202302117A (zh) 2023-01-16
US20220280537A1 (en) 2022-09-08
CA3210407A1 (en) 2022-09-09
JP2024512310A (ja) 2024-03-19
MX2023010313A (es) 2023-11-24
EP4301337A2 (en) 2024-01-10
WO2022187567A3 (en) 2022-10-20
CN117320727A (zh) 2023-12-29
WO2022187567A2 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
MX9207200A (es) Formulacion farmaceutica en aerosol, bote para suministrar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
US20210030965A1 (en) Single use delivery device
CO5031245A1 (es) Inhaladores de dosis regulada a presion y formulaciones farmaceuticas de aerosol
CO5680461A2 (es) Productos farmaceuticos que comprenden bisfosfonatos
AR058838A1 (es) Metodo para tratar el dano articular
NO20010091L (no) Medisinsk leveringsinnretning og en patronsammenstilling for bruk med denne
ES2824787T3 (es) Soluciones embaladas de alta estabilidad de hormona tiroidea T4
RU2740910C2 (ru) Офтальмологическая композиция, содержащая повидон-иод
AR014176A1 (es) Composiciones farmaceuticas de trifosfato de uridina.
JP2023002627A (ja) 眼科組成物
MX2018000258A (es) Dispositivo de suministro de un solo uso.
UY39658A (es) Formulación y métodos de gliburida de baja absorción
RU2012154628A (ru) Фармацевтическая композиция ибупрофена для инъекции
CO2021002433A2 (es) Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente
CN101674803A (zh) 浓艾司洛尔
RU2015119223A (ru) Система дозированного распределения
JP2022166168A (ja) 眼科組成物
WO2014120293A1 (en) Ophthalmic formulations
MX2015004962A (es) Composicion inyectable estable que contiene diclofenaco y tiocolchicosido.
JP2007186466A (ja) 樹脂容器中の生理活性ペプチドの安定性改善方法
CO2018009584A2 (es) Composición anestésica tópica
RU2002129356A (ru) Комбинация лекарственных средств для лечения головной боли, содержащая нестероидное противовоспалительное лекарственное средство
WO2017183714A1 (ja) 眼科組成物
AR083893A1 (es) Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente
JP2004091469A (ja) 光に安定なカルシトニン水溶液